The official blog of the Lung Institute.

Late Stage Lung Disease Sufferers Now Exploring Stem Cell Therapies as Alternative to Lung Transplantation

30 Oct 2013
| Under Press | Posted by | 0 Comments

The Lung Institute Educates the Public on the Restorative Nature of Regenerative Medicine in Support of Healthy Lung Month

Tampa, Fla. (October 30, 2013) – Regenerative medicine is the latest medical technology for the promotion of healing of lung tissue affected by lung disease. The Lung Institute’s physicians have harnessed this advancement in modern medicine to bring patients with conditions like chronic obstructive pulmonary disease (COPD), pulmonary fibrosischronic bronchitis and emphysema an innovative treatment choice that betters their quality of life and helps them to breathe easier.

Often, many of these patients have been told that lung transplantation is their only option, and as a result many are turning to advanced treatments such as pulmonary stem cell therapies to enhance lung function and promote healing. Here’s some information about how Stem Cell Therapies as Alternative to Lung Transplantation could be beneficial for people with chronic lung diseases.

How do Stem Cells Help Damaged Lung Tissue?

The Lung Institute utilizes autologous stem cells, meaning those derived from the patient’s own blood or bone marrow, for treatment. These adult stem cells have the unique ability to self-renew and replicate, and they are capable of forming any type of tissue found in the human body including lung tissue.

Both stem cell therapies and lung transplantation have been proven, in many cases, to improve quality of life. However, lung transplantation is an invasive inpatient surgery that has far riskier complications and a longer recovery time.

About Lung Institute

The Lung Institute is a leading medical provider of regenerative cellular therapy for lung diseases such as COPD, pulmonary fibrosis and interstitial lung disease. Founded in 2013 in Tampa, Fla., the Lung Institute currently has clinics in Tampa, Fla., Nashville, Tenn., Scottsdale, Ariz., Pittsburgh, Pa. and Dallas, Texas. For more information, please visit www.lunginstitute.com or call (800) 729-3065.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.